InvestSMART

Alterity Therapeutics Limited (ASX: ATH) - Announcements

- Current share price for ATH : $0.415

ASX company news and announcements for Alterity Therapeutics Limited (ATH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Alterity Therapeutics Limited (ATH) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Alterity Therapeutics Limited (ATH), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Alterity Therapeutics Limited (ATH)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$95 Trading Halt 4 Sep 2025 9:09AM $0.013 $0.415 risen by 3,092.31%
$95 Alterity Therapeutics Filed Form 20-F and XBRL Data with SEC 2 Sep 2025 11:17AM $0.014 $0.415 risen by 2,864.29%
$95 Alterity Therapeutics to Present at the Biotech Showcase 1 Sep 2025 10:06AM $0.013 $0.415 risen by 3,092.31%
$95 Corporate Governance Statement 29 Aug 2025 10:17AM $0.013 $0.415 risen by 3,220%
$95 Appendix 4G 29 Aug 2025 10:14AM $0.013 $0.415 risen by 3,220%
$95 Appendix 4E and 2025 Annual Report 29 Aug 2025 9:49AM $0.012 $0.415 risen by 3,358.33%
$95 Application for quotation of securities - ATH 22 Aug 2025 2:10PM $0.013 $0.415 risen by 3,092.31%
$95 Notification regarding unquoted securities - ATH 15 Aug 2025 2:53PM $0.013 $0.415 risen by 3,092.31%
$95 Notification regarding unquoted securities - ATH 15 Aug 2025 2:51PM $0.013 $0.415 risen by 3,092.31%
$95 Response to ASX Query Letters 4 Aug 2025 12:42PM $0.014 $0.415 risen by 2,864.29%
$95 Updated Corporate Presentation 31 Jul 2025 8:47AM $0.014 $0.415 risen by 2,864.29%
$95 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jul 2025 10:13AM $0.014 $0.415 risen by 2,864.29%
$95 Positive ATH434 Results from Open-Label Phase 2 Trial in MSA 28 Jul 2025 9:59AM $0.016 $0.415 risen by 2,493.75%
$95 Change in substantial holding 28 Jul 2025 8:18AM $0.016 $0.415 risen by 2,493.75%
$95 Peer-Reviewed Publication on Novel MRI Endpoint from bioMUSE 24 Jul 2025 10:08AM $0.014 $0.415 risen by 2,864.29%
$95 Application for quotation of securities - ATH 21 Jul 2025 11:33AM $0.014 $0.415 risen by 2,864.29%
$95 Application for quotation of securities - ATH 17 Jul 2025 2:06PM $0.013 $0.415 risen by 3,092.31%
$95 Response to ASX Price Query 14 Jul 2025 9:21AM $0.015 $0.415 risen by 2,666.67%
$95 Change in substantial holding 7 Jul 2025 8:20AM $0.010 $0.415 risen by 4,050%
$95 Notification regarding unquoted securities - ATH 3 Jul 2025 10:13AM $0.009 $0.415 risen by 4,511.11%
$95 Notification of cessation of securities - ATH 30 Jun 2025 12:01PM $0.010 $0.415 risen by 4,050%
$95 Alterity CEO to Provide Corporate Update on ATH434 23 Jun 2025 11:38AM $0.011 $0.415 risen by 3,672.73%
$95 Change in substantial holding 23 May 2025 8:20AM $0.011 $0.415 risen by 3,672.73%
$95 Alterity Prominently Featured at International MSA Congress 12 May 2025 9:54AM $0.010 $0.415 risen by 4,050%
$95 Change in substantial holding 12 May 2025 8:16AM $0.010 $0.415 risen by 4,050%

101 - 125 of 575 results

Page 5 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.